Acyclovir Sodium and Twinrix Adult

• Generic Name: acyclovir
• Dosage Forms: n.a.
• Other Brand Names: Sitavig, Zovirax

Treatment of initial and recurrent mucocutaneous HSV-1 and HSV-2 infections (e.g., orofacial, esophageal, genital, nasal, labial) in immunocompromised adults, adolescents, and children, including HIV-infected individuals. Drug of choice.

Chronic suppressive or maintenance therapy (secondary prophylaxis) of recurrent HSV infections in immunocompromised adults, adolescents, and children, including HIV-infected individuals who have frequent or severe recurrences.

Treatment of orolabial HSV infections (including gingivostomatitis) in immunocompetent adults and children; generally ineffective or minimally effective for prevention of recurrence of herpes labialis in immunocompetent individuals.

Treatment of eczema herpeticum in patients with a history of atopic dermatitis.

Treatment of HSV keratitis in HIV-infected patients.

Prophylaxis against recurrence of ocular HSV disease in immunocompetent adults and children ≥12 years of age who had ocular HSV disease (blepharitis, conjunctivitis, epithelial keratitis, stromal keratitis, iritis) in one or both eyes within the preceding 12 months. Has been used for prophylaxis after penetrating keratoplasty for herpetic keratitis.

Drug of choice for treatment of HSV encephalitis.

Drug of choice for treatment of neonatal HSV infections, including mucocutaneous infections, infections involving skin, eyes, and mouth, and disseminated or CNS infections.

Drug of choice for prevention of HSV recurrence in hematopoietic stem cell transplant (HSCT) recipients seropositive for HSV; such prophylaxis not indicated in those seronegative for HSV.

Treatment of initial episodes of genital herpes in adults and adolescents, including HIV-infected individuals.

Treatment of first episodes of herpes proctitis.

Episodic treatment of recurrent episodes of genital herpes in adults and adolescents, including HIV-infected individuals.

Chronic suppressive therapy of recurrent episodes of genital herpes in adults and adolescents, including HIV-infected individuals.

CDC and others recommend oral acyclovir, oral famciclovir, or oral valacyclovir as drugs of choice for treatment of initial episodes of genital herpes and for episodic treatment or chronic suppressive therapy of recurrent genital herpes.

Treatment of varicella (chickenpox) in immunocompromised adults, adolescents, and children, including HIV-infected individuals. Drug of choice.

Treatment of varicella (chickenpox) in immunocompetent adults, adolescents, and children. Varicella usually is a self-limited disease in otherwise healthy individuals and the role of acyclovir for treatment in these individuals is controversial; routine use not recommended by AAP and other clinicians.

Treatment of herpes zoster (shingles, zoster) in immunocompetent or immunocompromised adults, adolescents, and children, including HIV-infected individuals. Drug of choice for serious or disseminated herpes zoster in immunocompromised patients.

Treatment of herpes zoster ophthalmicus in HIV-infected patients.

Treatment of dermatomal herpes zoster in immunocompromised patients including transplant recipients and HIV-infected patients.

Alternative to varicella-zoster immune globulin (VZIG) for postexposure prophylaxis of VZV infection in HSCT recipients. Although long-term prophylaxis not routinely recommended for prevention of recurrent VZV infections in HSCT recipients, such prophylaxis may be considered in those with severe, long-term immunodeficiency.

Has been used for prevention of CMV disease in solid organ transplant recipients and bone marrow transplant (BMT) recipients at risk for the disease; data regarding efficacy are conflicting.

Has been used for prevention of CMV disease in HSCT recipients; generally ineffective after autologous HSCT. Ganciclovir is drug of choice for prevention of CMV following autologous or allogeneic HSCT in adults, adolescents, and children.

Not effective for prevention of CMV disease in HIV-infected individuals.

Treatment of uncomplicated or complicated infectious mononucleosis, chronic infectious mononucleosis, and various disorders (e.g., oral hairy leukoplakia) associated with Epstein-Barr virus infections; efficacy appears to be variable.

• Generic Name: hepatitis a adult vaccine / hepatitis b adult vaccine
• Dosage Forms: n.a.
• Other Brand Names: Twinrix Preservative-Free, Twinrix

Hepatitis A and hepatitis B combination vaccine is used to prevent infection caused by the hepatitis A and hepatitis B virus. The vaccine works by causing your body to produce its own protection (antibodies) against the disease.

Hepatitis A is a serious disease of the liver that can cause death. It is caused by the hepatitis A virus (HAV), and is spread most often through infected food or water. Hepatitis A may also be spread by close person-to-person contact with infected persons (such as between persons living in the same household). Although some infected persons do not appear to be sick, they are still able to spread the virus to others.

Hepatitis A is less common in the U.S. and other areas of the world that have a higher level of sanitation and good water and sewage (waste) systems. However, it is a significant health problem in parts of the world that do not have such systems. If you are traveling to certain countries or remote (out-of-the-way) areas, hepatitis A vaccine will help protect you from hepatitis A disease.

Hepatitis B is caused by hepatitis B virus (HBV), and is spread by contact with body fluids, such as blood, saliva, semen, or vaginal fluids; by needle sticks or sharing needles; or from mother to child.

Hepatitis A and hepatitis B combination vaccine is recommended for all persons 18 years of age or older who are at risk from infection from their jobs or some behaviors, or from traveling to the following parts of the world:

• Africa.
• Central and South America.
• Eastern and Southern Europe.
• South and Southeast Asia (except Japan).
• The Caribbean.
• The Middle East.
• The former Soviet Union

Hepatitis A and Hepatitis B combination vaccine is also recommended for:

• Military personnel.
• Persons living in or moving to areas that have a high rate of HAV infection and who are at a high risk of HBV infection.
• Persons engaging in high-risk sexual activity, such as homosexual and bisexual males.
• Persons who use illegal injection drugs.
• Persons at risk through their work, such as laboratory workers who handle live hepatitis A and hepatitis B virus, police, and those who give first aid or medical help, and workers who come in contact with stool or sewage.
• People who work in child daycare centers and correctional facilities, residents of drug and alcohol treatment centers, and patients and staff in hemodialysis units.
• People who are at increased risk for HBV infection and who are in close contact with patients that have hepatitis A or B.
• Persons with hemophilia.
• Persons with chronic liver disease.

This vaccine is to be given only by or under the supervision of a doctor.